New York, United States, November 2025 — Neurvati Neurosciences, the neuroscience development platform of Blackstone Life Sciences, today announced the appointment of Carlos Martin as Chief Commercial Officer (CCO). — Martin brings more than 20 years of leadership experience across global biopharmaceutical markets, with a strong record of building commercial organizations, launching transformative therapies, and strengthening pipeline valuation in innovative fields such as gene therapy, radiopharma, oncology, cardiology, and rare diseases.
Martin most recently served as Chief Commercial Officer at Rocket Pharmaceuticals, where he oversaw the company’s transition from a clinical-stage biotech to a commercial-ready gene therapy organization. He developed commercialization strategies across the U.S., EU, and Japan, built go-to-market models including infrastructure, and secured pre-launch payer agreements to accelerate market entry and enhance investor confidence. Earlier in his career, Martin held senior leadership roles at Novartis Pharmaceuticals. At Advanced Accelerator Applications (a Novartis company), he established the radiopharma commercial business in the U.S. At Novartis Oncology, he managed a $1B portfolio in the U.S. market and later served as Novartis Oncology Country Head in Chile, where he built a new business unit.
“Carlos brings exactly the kind of experience Neurvati needs at this moment,” said Bruce Leuchter, M.D., President & CEO of Neurvati. “He has repeatedly built commercial organizations in innovative therapeutic areas and modalities. From large markets in oncology and cardiology to neurology rare diseases, he has successfully translated clinical data into market value and led teams that deliver growth on a global scale. At Neurvati, his leadership will ensure that our transformational scientific advances are properly translated to the market and that our therapies are commercially and operationally prepared to succeed in the future.”
Neurvati’s model is designed to advance clinically validated programs with a clear trajectory toward patient impact and market value. The creation of the Chief Commercial Officer role reflects Neurvati’s commitment to integrating commercial strategy early to ensure that neuroscience therapies deliver strong value for patients, HCPs, payors, health systems and society. This approach ensures Neurvati and its affiliate companies are ready well ahead of launch.
“Neurvati’s vision of combining the focus of a biotech with the capital strength of best-in-class biopharma investment creates a powerful platform for innovation in neuroscience,” said Martin. “Having the opportunity to build a new global commercial framework to ensure Neurvati’s business is set up to deliver therapies to patients who urgently need them is the opportunity of a lifetime. I look forward to strengthening the company’s long-term strategic and financial position while building the future of the business alongside this talented team.”
With Martin’s appointment, Neurvati reinforces its model as a neuroscience company built for impact — bridging rigorous science with the scientific, operational, and commercial expertise required to deliver breakthroughs to patients globally.
About Radiprodil
Radiprodil is an investigational, potent negative allosteric modulator that selectively targets the GluN2B subunit of the NMDA receptor and is being evaluated for GRIN-related neurodevelopmental disorder (GRIN-NDD). It has received Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration, as well as PRIME designation and orphan designation opinion from the European Medicines Agency (EMA). A global Phase 3 trial will evaluate seizure outcomes, behavioral improvements, and functional outcomes. Radiprodil is also being developed for tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II, with the ongoing Astroscape trial (NCT06392009) assessing safety, tolerability, PK, and potential efficacy.
About GRIN Therapeutics
GRIN Therapeutics, Inc. develops precision therapeutics for pediatric neurodevelopmental disorders. The company recently reported promising Phase 1b/2a data from the Honeycomb Trial (NCT05818943) in GRIN-NDD, prompting advancement to a global pivotal Phase 3 trial. It is also evaluating radiprodil for TSC and FCD type II. GRIN Therapeutics is an affiliate of Neurvati Neurosciences, a Blackstone Life Sciences portfolio company.
About Neurvati Neurosciences
Neurvati Neurosciences, the neuroscience development platform of Blackstone Life Sciences, accelerates high-potential neuroscience programs through a disciplined, scalable model that forms and funds fit-for-purpose affiliate companies. Neurvati aims to overcome historical constraints in neuroscience drug development by integrating precision development, dedicated capital, and experienced leadership.
About Blackstone Life Sciences
Blackstone Life Sciences is an industry-leading investment platform with more than $12 billion in assets under management. It provides scale investment and hands-on operational expertise to advance promising medicines and medical technologies across the life sciences sector.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
